Irritable Bowel Syndrome Treatment Market Projections: Reaching $2.01 Billion Globally by 2026 with 8.2% CAGR, States Allied Market Research

Allied Market Research recently published a report, titled, "Irritable Bowel Syndrome Treatment Market by Type (IBS with Diarrhea (IBS-D), IBS with Constipation (IBS-C), and Mixed IBS (IBS-M), Product (Rifaximin, Eluxadoline, Lubiprostone, Linaclotide, and Others), and End User (Hospitals Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2019-2026". According to the report, the global irritable bowel syndrome treatment industry was pegged at $1.07 billion in 2018 and is expected to reach $2.01 billion by 2026, registering a CAGR of 8.2% from 2019 to 2026.

Understanding Irritable Bowel Syndrome:

Irritable bowel syndrome (IBS) represents a prevalent gastrointestinal disorder impacting the large intestine. Manifesting through abdominal pain, bloating, gas, cramping, and alternating constipation and diarrhea, IBS poses significant challenges to patients' quality of life. Treatment strategies encompass stress management, dietary adjustments, pharmacotherapy, and counseling. Medicinal options include rifaximin, eluxadoline, lubiprostone, linaclotide, alongside antispasmodics like dicyclomine, peppermint oil, and hyoscyamine.

Driving Factors:

Factors fueling market growth encompass the aging populace, escalating gastrointestinal disorders prevalence, stress levels elevation, and dietary inadequacies. Additionally, heightened awareness initiatives regarding IBS management, coupled with a growing preference for products enhancing therapeutic efficacy, stimulate market expansion. Furthermore, untapped potential within emerging economies offers lucrative growth prospects. However, challenges such as the absence of universally effective treatments for IBS symptoms and intensified competition, particularly in terms of pricing, may impede market progress.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐚𝐭: https://www.alliedmarketresearch.com/request-sample/6313

Market Segmentation:
The IBS treatment market is segmented by type (IBS-D, IBS-C, Mixed IBS), product (rifaximin, eluxadoline, lubiprostone, linaclotide, others), end-user (hospitals pharmacies, drug stores & retail pharmacies, online pharmacies), and region (North America, Europe, Asia-Pacific, LAMEA).

Insights into Segments:

IBS-D segment dominates the market, propelled by rising gastrointestinal disorder prevalence and increased drug adoption.
Rifaximin emerges as the leading product category, driven by escalating IBS prevalence and technological advancements enhancing treatment efficacy.
Asia-Pacific presents substantial growth opportunities due to rising awareness, healthcare infrastructure improvements, and expanding R&D initiatives.
Key Players and Stakeholder Benefits:
Major industry players such as Abbott Laboratories, Allergan plc, Astellas Pharma Inc., among others, are actively shaping market dynamics. Stakeholders benefit from comprehensive market insights spanning from 2018 to 2026, aiding in identifying investment opportunities and understanding competitive landscapes. Moreover, geographical analyses enable stakeholders to capitalize on prevailing market opportunities.

𝐅𝐨𝐫 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐄𝐧𝐪𝐮𝐢𝐫𝐲 𝐚𝐭: https://www.alliedmarketresearch.com/purchase-enquiry/6313

𝐒𝐢𝐦𝐢𝐥𝐚𝐫 𝐑𝐞𝐩𝐨𝐫𝐭𝐬:

✅ Artificial Organs and Bionic Implants Market - https://www.alliedmarketresearch.com/artificial-organs-and-bionics-market-A14360

✅ Teledermatology Market - https://www.alliedmarketresearch.com/tele-dermatology-market-A14386

✅ Wound Care Biologics Market -
https://www.alliedmarketresearch.com/wound-care-biologics-market-A10347

✅ Medical Rehabilitation Services Market - https://www.alliedmarketresearch.com/medical-rehabilitation-services-market-A110797

✅ Laboratory Informatics Market - https://www.alliedmarketresearch.com/laboratory-informatics-market-A109163

✅ Irritable Bowel Syndrome Treatment Market size, share -
https://www.alliedmarketresearch.com/irritable-bowel-syndrome-treatment-market-A05948

Contact Us:
David Correa
1209 Orange Street,
Corporation Trust Center,
Wilmington, New Castle,
Delaware 19801 USA.
Int'l: +1-503-894-6022
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
India (Pune): +91-20-66346060
Fax: +1-800-792-5285
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.